parathyroid hormone abaloparatide
Selected indexed studies
- Osteoporosis: A Review. (JAMA, 2025) [PMID:40587168]
- Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist. (Ann Pharmacother, 2018) [PMID:29241341]
- Advances in Parathyroid Hormone-based medicines. (J Bone Miner Res, 2025) [PMID:40847810]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. (2016) pubmed
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. (2023) pubmed
- Osteoporosis: A Review. (2025) pubmed
- Drug therapy for osteoporosis in older adults. (2022) pubmed
- Advances in Parathyroid Hormone-based medicines. (2025) pubmed
- Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist. (2018) pubmed
- Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. (2023) pubmed
- Parathyroid Hormone-Related Peptide and Its Analog, Abaloparatide, Attenuate Lethal Myocardial Ischemia-Reperfusion Injury. (2022) pubmed
- Parathyroid hormone receptor agonists in the management of osteoporosis. (2025) pubmed
- Osteoporosis. (2019) pubmed